Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals

Multiple Sclerosis Drugs - Israel

Israel
  • The Multiple Sclerosis Drugs market in Israel is expected to witness significant growth in the coming years.
  • According to projections, the revenue is projected to reach US$58.84m in 2024.
  • Moreover, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2029) of 1.13%, leading to a market volume of US$62.23m by 2029.
  • When compared to other countries globally, United States is forecasted to generate the highest revenue in the Multiple Sclerosis Drugs market, with an estimated revenue of US$11.77bn in 2024.
  • Israel has seen a surge in research and development for innovative multiple sclerosis drugs, positioning itself as a leading player in the global market.

Definition:
This market covers drugs to treat the neurological autoimmune disease multiple sclerosis. As there is no cure for multiple sclerosis, the goal is to improve functions after an attack or to prevent attacks. Different types of medication include immunomodulators, immunosuppressants, and interferons. Monoclonal antibodies are now being increasingly used.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Biogen, Roche, Novartis, Sanofi

In-Scope

  • Drugs to treat multiple sclerosis
  • Monoclonal antibodies
  • Immunosuppressants

Out-Of-Scope

  • Monoclonal antibodies and immunosuppressants for the treatment of other diseases
  • Treatment of other autoimmune diseases
  • Alternative medicine
Multiple Sclerosis Drugs: market data & analysis - Cover

Market Insights report

Multiple Sclerosis Drugs: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Most recent update: Mar 2024

    Source: Statista Market Insights

    Analyst Opinion

    The Multiple Sclerosis Drugs market in Israel has been showing steady growth in recent years.

    Customer preferences:
    Customers in Israel prefer drugs that are effective in treating multiple sclerosis while having minimal side effects. They also prefer drugs that are affordable and easily accessible. Patients in Israel have a high level of awareness about the disease and its treatment options. They are well-informed and actively participate in their treatment decisions.

    Trends in the market:
    The Multiple Sclerosis Drugs market in Israel has been growing due to the increasing prevalence of multiple sclerosis in the country. The market is also driven by the introduction of new drugs with better efficacy and fewer side effects. The market is highly competitive with many players offering a wide range of drugs for the treatment of multiple sclerosis. There is also a trend towards personalized medicine, with drugs being tailored to the individual needs of patients.

    Local special circumstances:
    Israel has a high prevalence of multiple sclerosis, with around 12,000 people living with the disease. The country has a well-developed healthcare system, which provides access to advanced treatments and therapies. The government provides subsidies for the treatment of multiple sclerosis, making it more affordable for patients. The country is also home to several research institutions that are actively engaged in the development of new drugs and therapies for the treatment of multiple sclerosis.

    Underlying macroeconomic factors:
    The Israeli economy has been growing steadily in recent years, with a focus on innovation and technology. This has led to the development of a strong pharmaceutical industry in the country. The government has also been actively promoting the development of the healthcare sector, which has led to increased investment in research and development. The aging population in Israel is also contributing to the growth of the Multiple Sclerosis Drugs market, as the disease is more prevalent in older individuals.

    Next generation therapy

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Multiple Sclerosis Drugs: market data & analysis - BackgroundMultiple Sclerosis Drugs: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Global pharmaceutical industry - statistics & facts

    The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.